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httpcense.Abstract Background: Idiopathic pulmonary ﬁbrosis (IPF) is deﬁned as a speciﬁc form of chronic
ﬁbrosing interstitial pneumonia limited to the lung, with the histopathology of UIP on surgical lung
biopsy. Recent epidemiological evidence indicates that patients with IPF have an increased risk of
cardiovascular disease. The vascular endothelium acts to maintain vascular homeostasis through
multiple mechanisms, and alteration in its function precedes the development, progression and clin-
ical expression of atherosclerosis.
Aim of the work: To assess the prevalence of endothelial dysfunction in patients with idiopathic
pulmonary ﬁbrosis and its correlation with pulmonary hypertension.
Subjects and methods: The study included two groups. The patient group included 30 IPF
patients subdivided into 2 subgroups: Subgroup I (15 IPF cases) with pulmonary hypertension;
Subgroup II (15 IPF cases) without pulmonary hypertension. The control group included 10 normal
healthy individuals. Patients were subjected to written informed consent, detailed history taking,
thorough clinical examination, collagen proﬁle, arterial blood gases (PaO2, SaO2), Pulmonary func-
tion tests (spirometry), 6 min walk test, HRCT chest scan, echocardiography, and brachial artery
duplex to assess endothelial dysfunction.
Results: Subgroup (I) and Subgroup (II) showed a statistically highly signiﬁcant difference in
brachial artery ﬂow mediated dilatation (BADFMD) and endothelium – reactive dilatation
(ERD) which indicate endothelial dysfunction compared to the control group.01649587.
m (H. Abdel-Haﬁz).
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590 M. Elshazly et al.Conclusion: This work concluded that BADFMD and ERD more affected in IPF patients
regardless of presence or absence of PH than normal population. So, endothelial dysfunction is a
possible link between IPF and cardiovascular disease.
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Idiopathic pulmonary ﬁbrosis (IPF) is deﬁned as a speciﬁc
form of chronic ﬁbrosing interstitial pneumonia limited to
the lung, with the histopathology of usual interstitial pneumo-
nia (UIP) on surgical (thoracoscopic or open) lung biopsy [1].
Pulmonary hypertension (PH) is frequently seen in patients
with IPF and is commonly attributed to hypoxic vasoconstric-
tion and capillary destruction. Pathology ﬁndings include
endothelial proliferation and medial hypertrophy that exceed
those expected in the setting of hypoxia [2–4].
Recent epidemiological evidence indicates an association
between cardiovascular diseases and pulmonary ﬁbrosis [5–
7]. The vascular endothelium acts to maintain vascular homeo-
stasis through multiple mechanisms and impaired endothelial
function can contribute to the development, progression and
clinical expression of atherosclerosis [8]. We hypothesized that
impaired endothelial function should have an increased preva-
lence among IPF patients.
Subjects and methods
The present study was conducted in Chest Department, Kasr
El-Aini Hospital in the period between August 2009 and au-
gust 2011. The cases were diagnosed as having IPF according
to the guidelines of the international consensus statement pro-
duced as a collaborative effort from the American thoracic
society and European respiratory society.
The study included 30 cases with IPF half of them with pul-
monary hypertension and other half without pulmonary
hypertension (Patient group) and 10 apparently healthy volun-
teers (Control group) after having their written consent prior
to participation in the study.
All patients were subjected basically to full history taking,
thorough clinical examination, routine laboratory investiga-
tions, arterial blood gases, spirometry, 6 min walk test, high
resolution CT chest, trans-thoracic echocardiography with
estimation of pulmonary artery systolic pressure and assess-
ment of endothelial dysfunction with duplex imaging on right
brachial artery.
The vasodilatory response of the brachial artery to increased
shear stress is called ﬂow mediated dilation (FMD), and reﬂects
the ability of vascular endothelium to produce NO. FMD of
the brachial artery following transient ischemia, which is a non-
invasive method for assessing endothelial function, was done
according to the method deﬁned by Celermajer et al. [9].
A high-resolution (10 MHz) linear array ultrasound trans-
ducer (GE vivid 3, SyncMaster 796 mb) was used.
Patients and control were kept in supine position and at sta-
ble room temperature. All cases abstained from vitamin C in-
take, fatty meals, smoking and caffeine-containing drinks for
at least 12 h before testing. In order to best visualize the bra-
chial artery, the arm was comfortably immobilized in the ex-tended position, and the brachial artery was scanned in the
longitudinal section 3-5 cm above the antecubital fossa. After
baseline measurements of the brachial artery were recorded,
the cuff was placed distal to the section of brachial artery
and inﬂated to 200 mmHg for 5 min to create forearm ische-
mia. Subsequently, the cuff was deﬂated and the arterial diam-
eter was measured at 60 s after deﬂation [10].
All measurements of the brachial artery internal diameter
(from media-adventitia interfaces to media-adventitia inter-
faces) were assessed at the end of the diastole (timed by the
QRS complex) to avoid any effect of arterial compliance on
the measurements. Mean baseline brachial artery diameter
(BADbasal) was measured in millimeters; peak FMD measured
in percentage and calculated as [(Dmax  BADbasal)/BADbasal]
· 100 [11].
Endothelium – reactive dilatation was expressed as the per-
centage of change in the brachial artery diameter from baseline
to following reactive hyperemia, i.e. percentage change = (-
BADFMD  BADbasal)/BADFMD · 100 [12].
Results
Table 1 shows the patients of IPF had a borderline statistically
signiﬁcant reduction in baseline brachial artery diameter in
comparison with normal Individuals (controls). But there
was no statistically signiﬁcant reduction in baseline brachial
artery diameter in IPF patients in the presence or absence of
PH.
Table 2 shows that BADFMD of the IPF patients with PH
ranged from 2.8 to 4.7 mm, whereas the BADFMD of the
IPF patients without PH ranged from 3.9 to 4.3 mm and the
BADFMD of the control group ranged from 4.3 to 5.1 mm.
The patients of IPF had a statistically highly signiﬁcant
lower dilatation response to ischemia and hypoxia in brachial
artery diameter (brachial artery ﬂow-mediated dilatation
BADFMD) than normal individuals (controls). But there was
no statistically signiﬁcant low response to ischemia and hypox-
ia in brachial artery diameter (BADFMD) in IPF patients in the
presence or absence of PH.
Table 3 shows that ERD of the IPF patients with PH ran-
ged from 4.9% to 12.8%, whereas the ERD of the IPF patients
without PH ranged from 4.6 to 12.8% and the ERD of the
control group ranged from 11.6% to 16.3%.
The patients of IPF had a statistically highly signiﬁcant
reduction in endothelium–reactive dilatation (ERD)% in com-
parison with normal individuals (controls). But there was no
statistically signiﬁcant in endothelium–reactive dilatation
(ERD)% in IPF patients in the presence or absence of PH.
Discussion
The aim of the current study was to assess the prevalence of
endothelial dysfunction in patients with idiopathic pulmonary
ﬁbrosis and its correlation with pulmonary hypertension.
Table 1 Statistical comparison of BADbasal between the patient group and control group.
BAD basal IPF with PAH
(n= 15) Mean ± S.D
IPF without PAH
(n= 15) Mean ± S.D
Control group (n= 10)
Mean ± S.D
Total
(n= 40) Mean ± S.D
P-Value Statistical
signiﬁcance
BAD basal (mm) 3.79 ± 0.48 3.83 ± 0.32 4.14 ± 0.22 3.89 ± 0.39 0.062 Borderline S
Deﬁnition of abbreviations: SD= standard deviation, borderline S = borderline signiﬁcant.
(P> 0.05ﬁ non signiﬁcant, P< 0.05ﬁ signiﬁcant, P< 0.01ﬁ highly signiﬁcant).
Table 2 Statistical comparison of BADFMD between the patient group and control group.
BAD (FMD) IPF with PAH
(n= 15) Mean ± S.D
IPF without PAH
(n= 15) Mean ± S.D
Control group
(n= 10) Mean ± S.D
Total
(n= 40) Mean ± S.D
P-Value Statistical
signiﬁcance
BAD FMD (mm) 4.15 ± 0.55 4.17 ± 0.19 4.82 ± 0.29 4.32 ± 0.47 0.001 H.S
Deﬁnition of abbreviations: SD= standard deviation, HS = highly signiﬁcant.
(P> 0.05ﬁ non signiﬁcant, P< 0.05ﬁ signiﬁcant, P< 0.01ﬁ highly signiﬁcant).
Table 3 Statistical comparison of ERD between the patient group and control group.
ERD IPF with PAH
(n= 15) Mean ± S.D.
IPF without PAH
(n= 15) Mean ± S.D.
Control group
(n= 10) Mean ± S.D.
Total (n= 40)
Mean ± S.D.
P-Value Statistical
signiﬁcance
ERD (%) 8.75 ± 2.16 8.13 ± 3.6 14.04 ± 1.60 9.84 ± 3.60 0.001 H.S
Deﬁnition of abbreviations: SD= standard deviation, HS = highly signiﬁcant.
(P> 0.05ﬁ non signiﬁcant, P< 0.05ﬁ signiﬁcant, P< 0.01ﬁ highly signiﬁcant).
ERD: Endothelial reactive dilatation = (BADFMD  BADbasal)/BADFMD · 100.
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tion assessment is duplex ultrasound to measure brachial ar-
tery ﬂow-mediated dilatation (BADFMD), which is dependent
on the availability of nitric oxide released from endothelial
cells. It follows that the greater the FMD the better the endo-
thelial function. However, using duplex ultrasound is techni-
cally challenging, requires highly skilled operators, is
expensive and therefore difﬁcult to use as a readily available
screening tool [11].
Despite limitations in visualization of the right heart, and
operator dependence, trans-thoracic echocardiography (TTE)
is a useful and readily available tool for evaluation of PH
[13]. Tricuspid peak Doppler ﬂow velocity correlates well with
hemodynamic parameters and systolic PAP is relatively sensi-
tive (79–100%) and speciﬁc (60–98%) for the presence of PH
[14]. TTE is the recommended tool for screening and early
detection of PH by the American College of Chest Physicians
[15].
Table 2 shows that patients of IPF had a highly statistically
signiﬁcant lower response to ischemia and hypoxia in brachial
artery diameter (brachial artery ﬂow-mediated dilatation
BADFMD) than normal individuals (controls). But there was
no statistically signiﬁcant low response to ischemia and hypox-
ia in brachial artery diameter (BADFMD) in IPF patients in the
presence or absence of PH.
Table 3 shows that patients of IPF had a highly statistically
signiﬁcant reduction in endothelium–reactive dilatation
(ERD)% in comparison with normal individuals (controls).
But there was no statistically signiﬁcant in Endothelium-reac-
tive dilatation (ERD)% in IPF patients in the presence or ab-
sence of PAH.These results were incompatible with the results of Hughes
et al. [16], Peled et al. [17]. who found that systemic component
of endothelial dysfunction might be involved in PAH that is
correlated with disease severity. This can be explained by that
these two studies were done on idiopathic pulmonary arterial
hypertension but in this study it was done on cases with PH
secondary to IPF which has different pathophysiology.
The systemic involvement might be related primarily to the
disease pathobiology, or mediated by a high activity of circu-
latory mediators such as pro-inﬂammatory cytokines [18],
alterations in metabolic pathways of serotonin [19], prothrom-
botic abnormalities [20], hypoxia and sympathetic muscle
nerve overactivity [21], or alteration in systemic metabolism
[22]. So this ﬁnding may indicate a tight linkage between the
pulmonary disease and the peripheral endothelium. However,
the exact contribution of each factor to the peripheral endothe-
lial dysfunction needs to be further investigated in longitudinal
studies.
This work concluded that BADFMD and ERD were more
affected in IPF patients regardless of presence or absence of
PH than normal population. So, endothelial dysfunction is a
possible link between IPF and cardiovascular disease.
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